title: Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.
abstract: Hepatitis C virus (HCV) is the most common blood-borne infection in the United States. The high morbidity and mortality due to untreated infection have prompted updated screening recommendations that now include one-time HCV screening for all patients born between 1945 and 1965, in addition to risk factor-based screening. Current guidelines recommend treatment for all patients with chronic HCV. Treatment for HCV genotype 1 has evolved dramatically since the approval of the direct-acting antivirals. The approval of ledipasvir-sofosbuvir, ombitasvir-paritaprevir-ritonavir and dasabuvir, and simeprevir with sofosbuvir has dramatically altered the treatment landscape. High sustained virologic response (SVR) rates favor treatment, yet access to care poses a challenge for patients and providers. Current and emerging data with new therapies indicate high SVR rates in treatment-naïve and treatment-experienced patients, including patients with cirrhosis and in other special populations. Additional data suggest the addition of ribavirin can decrease treatment duration without compromising SVR rates. Resistance is an increasing area of interest in HCV, with baseline mutations identified and the potential for the development of resistance-associate variants in patients undergoing treatment. Due to the rapid evolution of HCV treatment, pharmacists should address challenges and play an integral role in agent selection, dosing, drug interaction screening, adverse effect monitoring, and the coordination of treatment. Clinical application of the latest information will reduce patient risk and improve outcomes.
authors: Department of Pharmacy Practice, University of New Mexico College of Pharmacy, Albuquerque, New Mexico.
authors: Paulina
authors: P
authors: Deming
authors: Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, University of Illinois Hospital and Health Sciences System, Chicago, Illinois.
authors: Michelle T
authors: MT
authors: Martin
authors: Colleges of Pharmacy and Medicine, University of Illinois at Chicago, Chicago, Illinois.|Gastroenterology/Hepatology, Illinois Department of Corrections Hepatology Telemedicine, Sections of Hepatology, Digestive Diseases and Nutrition, University of Illinois Hospital & Health Sciences Center, Chicago, Illinois.
authors: Juliana
authors: J
authors: Chan
authors: Department of Pharmacy, Wheaton Franciscan Healthcare - St. Francis, Milwaukee, Wisconsin.|Center for AIDS Intervention Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
authors: Thomas J
authors: TJ
authors: Dilworth
authors: Pharmacy Education and Training, Department of Pharmacy Services, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE.
authors: Rania
authors: R
authors: El-Lababidi
authors: Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy, Columbia, South Carolina.
authors: Bryan L
authors: http://orcid.org/0000-0002-9221-9143
authors: BL
authors: Love
authors: Department of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michigan.|University of Michigan Health System, Ann Arbor, Michigan.
authors: Rima A
authors: RA
authors: Mohammad
authors: Gallup Indian Medical Center, Gallup, New Mexico.
authors: Amy
authors: A
authors: Nguyen
authors: Pharmacy Practice, School of Pharmacy Worcester/Manchester, MCPHS University, Worcester, Massachusetts.|Infectious Diseases, Saint Vincent Hospital, Worcester, Massachusetts.
authors: Linda M
authors: LM
authors: Spooner
authors: Penn Highlands DuBois, DuBois, Pennsylvania.
authors: Suzanne B
authors: SB
authors: Wortman
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D004338:Drug Combinations; D004347:Drug Interactions; D024921:Drug Resistance, Multiple, Viral; D004359:Drug Therapy, Combination / Q000009:adverse effects; D019317:Evidence-Based Medicine; D016174:Hepacivirus / Q000187:drug effects* / Q000302:isolation & purification; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology / Q000821:virology; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000503:physiopathology / Q000821:virology; D008103:Liver Cirrhosis / Q000209:etiology / Q000517:prevention & control; D008403:Mass Screening; D017410:Practice Guidelines as Topic; D012957:Societies, Pharmaceutical; D000072230:Sustained Virologic Response; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000998:Antiviral Agents; D004338:Drug Combinations
keywords: antivirals; dasabuvir; hepatitis C; ledipasvir-sofosbuvir; ombitasvir-paritaprevir-ritonavir; simeprevir; sofosbuvir